BCR inhibition achieved by Bruton tyrosine kinase (BTK) inhibitor ibrutinib represents effective therapy for many CLL patients but does not induce complete responses without continued therapy [60]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.